14 Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?

15 A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview.

16 From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans – Call for a One Health approach

17 Li Wenliang, a face to the frontline healthcare worker. The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak

18 The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

19 Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.

20 Safety Considerations in the Laboratory Testing of Specimens Suspected or Known to Contain the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

21 SARS-CoV-2 and COVID-19: The most important research questions.

22 Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

23 The novel Coronavirus (SARS-CoV-2) is a one health issue

24 Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?

25 Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion

26 An Overview of Severe Acute Respiratory Syndrome--Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

27 Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy.

28 Possible Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Public Bath Center in Huai'an, Jiangsu Province, China.

29 Response to: Sore throat in COVID-19: comment on "Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis".

30 Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Integrated Computational Approach.

31 SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes.

32 Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids.

33 Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.

34 F-FDG uptake in Asymptomatic SARS-CoV-2 (COVID-19) patient, referred to PET/CT for Non-Small Cells Lung Cancer restaging.

35 Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians

36 The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation?

37 The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.

38 Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.

39 Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection.

40 Nuclear medicine in SARS-CoV-2 pandemia: 18F-FDG-PET/CT to visualize COVID-19.

41 SARS-CoV-2 Vaccines: Status Report.

42 Infection and Rapid Transmission of SARS-CoV-2 in Ferrets.

43 Universal Screening for SARS-CoV-2 in Women Admitted for Delivery.

44 Stability and Viability of SARS-CoV-2. Reply.

45 Stability and Viability of SARS-CoV-2.

46 Stability and Viability of SARS-CoV-2.

47 Stability and Viability of SARS-CoV-2.

48 Stability and Viability of SARS-CoV-2.

49 Stability and Viability of SARS-CoV-2.

50 A field indoor air measurement of SARS-CoV-2 in the patient rooms of the largest hospital in Iran.

51 Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.

52 Clinical Trials during the SARS-CoV-2 Pandemic.

53 The evidence of SARS-CoV-2 infection on ocular surface.

54 [Obstetric Anesthesia During the SARS-CoV-2 Pandemic - a Brief Overview of Published Recommendations for Action by National and International Specialist Societies and Committees].

55 Supporting pandemic response using genomics and bioinformatics: a case study on the emergent SARS-CoV-2 outbreak.

56 Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?

57 Advanced forecasting of SARS-CoV-2 related deaths in Italy, Germany, Spain, and New York State.

58 Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.

59 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

60 Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant.

61 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review.

62 Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy.

63 The Architecture of SARS-CoV-2 Transcriptome.

64 Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

65 What do we know about the SARS-CoV-2 coronavirus in the environment?

66 Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient

67 A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

68 Occupational exposure to SARS-CoV-2 in burns treatment during the COVID-19 epidemic: Specific diagnosis and treatment protocol.

69 SARS-CoV-2 infection control measures for the anesthesiology department: experience from the Sichuan Provincial People's Hospital, China.

70 Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.

71 Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

72 Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories

73 The Malnutritional Status of the Host as a Virulence Factor for New Coronavirus SARS-CoV-2

74 Properties of Coronavirus and SARS-CoV-2.

75 Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity).

76 Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2.

77 Treatment of SARS-CoV-2: How far have we reached?

78 Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

79 COVID-19: Ophthalmological Aspects of the SARS-CoV 2 Global Pandemic.

80 Perspective: SARS-CoV-2, COVID-19 and Haematologists.

81 Structure-based Virtual Screening and Molecular Dynamic Simulation Studies of the Natural Inhibitors of SARS-CoV-2 Main Protease

82 Delivery in pregnant women infected with SARS-CoV-2: A fast review.

83 Validation of SARS-CoV-2 detection across multiple specimen types.

84 A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).

85 Sars-Cov-2 hurricane impacting proctology outpatient clinics and proctologic emergencies. On the verge of phase 2, learning from phase 1. Correspondence.

86 Lack of type 1 diabetes involvement in SARS-COV-2 population: Only a particular coincidence?

87 Electron microscopy of SARS-CoV-2: a challenging task.

88 Electron microscopy of SARS-CoV-2: a challenging task - Authors' reply.

89 Tale of three seeding patterns of SARS-CoV-2 in Saudi Arabia.

90 Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection (Nature Communications, (2020), 11, 1, (2251), 10.1038/s41467-020-16256-y)

91 Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome

92 Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M<sup>pro</sup>

93 SARS-CoV-2: the emergence of a viral pathogen causing havoc on human existence

94 COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms

95 A human monoclonal antibody blocking SARS-CoV-2 infection

96 The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

97 Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction

98 A “One-Health” approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy

99 Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

100 Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA

101 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Keyword Connections

Journals

Research Groups

Bibliographies